NK CellTech

Executive Summary

NK CellTech is a Shanghai-based biotechnology company focused on developing off-the-shelf, allogeneic natural killer (NK) cell therapies for cancer. Founded in 2016, the company leverages peripheral blood and stem cell sources to create readily available, cost-effective immunotherapies with improved safety profiles compared to T-cell therapies. Its lead candidate targets both solid tumors and hematologic malignancies, addressing key limitations of autologous CAR-T treatments such as scalability and accessibility. Currently at preclinical stage, NK CellTech has yet to disclose specific pipeline details or financing history. The company operates in a competitive landscape with several NK cell therapy developers, but its focus on allogeneic approaches and potential for broad applicability positions it for future clinical development. Success will depend on advancing its platform through IND-enabling studies and securing partnerships or funding to support first-in-human trials.

Upcoming Catalysts (preview)

• Q1 2027IND filing for lead NK cell therapy candidate50% success
• Q3 2026Presentation of preclinical efficacy data at major oncology conference75% success
• H2 2026Series B financing round to support IND-enabling studies65% success